Impact of COVID-19 on Survival and Relapse in Pediatric Cancer Patients
Archives of Pediatric Infectious Diseases · 08.10.2025 · 14 (4)
DOI: 10.5812/apid-160947 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Pediatric Infectious Diseases, online erschienen am 08.10.2025. Verfasst von Seyed Reza Abdipour Mehrian und 7 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) significantly affects vulnerable populations, including pediatric patients with malignancies.
Objectives
This study aimed to address knowledge gaps regarding COVID-19 in pediatric oncology patients by investigating clinical outcomes, complications, and risk factors.
Methods
In this retrospective cohort study, data from 9,171 hospitalized pediatric patients, including 146 COVID-19-positive patients, were analyzed. Clinical, demographic, and radiological data were collected, and statistical analyses were conducted using STATA version 17.
Results
During five national peaks, 9,171 pediatric patients were admitted to our tertiary oncology teaching hospital. Of these, 1,944 patients were tested for SARS-CoV-2 infection using polymerase chain reaction (PCR) assays, with 146 patients (7.5%) testing positive. Acute lymphoblastic leukemia (ALL) was the most prevalent malignancy (41%) in this study. The common presenting symptoms included fever (48%), generalized weakness (15%), and cough (15%). Radiological evaluation revealed no abnormalities in 38.58% of chest radiographs and 42.86% of computed tomography (CT) scans, whereas severe findings were noted in 11.02% and 7.14%, respectively. In this study, only 0.7% of COVID-positive patients required intensive care unit (ICU) admission, and 1.54% required mechanical ventilation. Among the COVID-positive patients, 22 (15%) died, with over 30% of these deaths occurring 10 days post-diagnosis, as indicated by the Kaplan-Meier survival estimate. Additionally, seven COVID-19-positive patients had a relapse of malignancy within 16 weeks of their COVID-19 diagnosis. The average time to relapse following SARS-CoV-2 infection was estimated to be 245.85 ± 213.24 days. Disease relapse [adjusted odds ratio (aOR): 2.09, P = 0.026], age < 12 months (aOR: 2.62, P = 0.010), and neuroblastoma diagnosis (aOR: 3.38, P = 0.005) were significantly associated with increased mortality in the multivariate analysis.
Conclusions
Although a 15% mortality rate was observed among pediatric oncology patients with COVID-19, multivariate analysis did not demonstrate a statistically significant association between COVID-19 infection and an increased risk of relapse or mortality after adjusting for confounding factors. These findings suggest that, despite the observed mortality, COVID-19 infection was not an independent predictor of adverse outcomes in this population.
Zitieren
APA
Mehrian, S. R. A., Pishdad, P., Mansouri, Z., Sharifi, M., Meftah, E., Farhadi, M., Habibzadeh, A., & Amanati, A. (2025). Impact of COVID-19 on Survival and Relapse in Pediatric Cancer Patients. Archives of Pediatric Infectious Diseases, 14(4). https://doi.org/10.5812/apid-160947
Vancouver
Mehrian SRA, Pishdad P, Mansouri Z, Sharifi M, Meftah E, Farhadi M, et al. Impact of COVID-19 on Survival and Relapse in Pediatric Cancer Patients. Archives of Pediatric Infectious Diseases. 2025;14(4). doi:10.5812/apid-160947
BibTeX
@article{Mehrian2025,
author = {Mehrian, Seyed Reza Abdipour and Pishdad, Parisa and Mansouri, Zahra and Sharifi, Maryam and Meftah, Elahe and Farhadi, Mohammad and Habibzadeh, Adrina and Amanati, Ali},
title = {Impact of COVID-19 on Survival and Relapse in Pediatric Cancer Patients},
journal = {Archives of Pediatric Infectious Diseases},
year = {2025},
volume = {14},
number = {4},
doi = {10.5812/apid-160947}
}
EUVIMED